The round was led by Amadeus Capital Partners, with participation from Asabys Partners and APEX Ventures. The funding will support clinical validation and commercial rollout of its MaiRa platform, which analyzes early signals of first-trimester pregnancy complications through blood tests.
Founded in 2019 and based in Valencia, iPremom uses molecular diagnostics and AI to predict risks like preeclampsia from a single blood sample as early as 9–14 weeks. The platform is built on data from over 26,000 samples and 10,000 pregnancies.